RESUMEN
BACKGROUND: Meyerson phenomenon (MP) consists of an eczematous reaction occurring around a pre-existing dermatologic lesion that is usually melanocytic and generally benign, and which is known as a Meyerson naevus. We report a case of multiple Meyerson naevi revealing melanoma, which itself was surrounded by a halo of eczema. PATIENTS AND METHODS: A 55-year-old man of phototype III with atopic eczema presented for pruritic eczema present for a fortnight, found solely on and around the naevi on his trunk and at roots of his limbs. One of the melanocytic lesions affected by these Meyerson phenomena was clinically atypical and had been active for several years. Excision confirmed the diagnosis of level II extensive superficial melanoma measuring 0.75 mm in thickness and associated with lesional and perilesional eczematous remodelling. After surgery involving a 1-cm excision margin and local corticosteroid therapy of the eczema, the Meyerson phenomenon subsided with complete remission of the melanoma at 1 year. DISCUSSION: Meyerson phenomenon can affect one or more naevi at the same time; it is generally transient, may recur on occasion, and has a favourable outcome either spontaneously or with corticosteroid treatment. When not removed for histological verification, the melanocytic lesion regains its initial appearance following resolution of the phenomenon. MP differs from Sutton phenomenon (SP), which is a perinaevic vitiligo reaction leading to complete or partial regression of the melanocytic lesion, which may be either benign or malignant. CONCLUSION: This case of Meyerson phenomenon revealing melanoma shows that the melanocytic lesions targeted by MP are not necessarily benign.
Asunto(s)
Melanoma/patología , Nevo/patología , Enfermedades Cutáneas Eccematosas/patología , Neoplasias Cutáneas/patología , Humanos , Masculino , Melanoma/complicaciones , Persona de Mediana Edad , Nevo/complicaciones , Enfermedades Cutáneas Eccematosas/complicaciones , Neoplasias Cutáneas/complicacionesRESUMEN
BACKGROUND: Post-radiation atypical vascular lesions of the skin display clinical and morphological overlap with well-differentiated angiosarcomas, and correct diagnosis may be difficult. PATIENTS AND METHODS: We studied clinical, histological and immuno-histochemical aspects (CD31, CD34, D2-40 and VEGFR-3) of eight post-radiation atypical vascular lesions comparatively with three post-radiation angiosarcomas. RESULTS: All patients were female and received radiation therapy for breast carcinoma. On average, atypical vascular lesions occurred 4.3 years after radiation therapy and presented as small papulonodules or erythematous plaques. The clinical course after simple excision was benign. Histologically, they were relatively circumscribed lesions and showed slit-like vessels dissecting dermal collagen in all cases. On average, angiosarcomas occurred 5 years after radiation therapy and presented as more extensive lesions with a more aggressive clinical course. The lesions showed histological overlap with atypical vascular lesions, but were poorly circumscribed, with deeper invasion, cytological atypia and mitosis. Although the immuno-histochemical profiles were similar, expression of VEGFR-3 was greater in two cases of angiosarcoma. CONCLUSION: Post-radiation atypical vascular lesions are benign lesions that display clinical, histological and immuno-phenotypic overlap with well-differentiated angiosarcoma, and diagnosis requires good clinicopathological correlation. VEGFR-3 may be useful for differential diagnosis, as well as amplification of the MYC gene.
Asunto(s)
Hemangiosarcoma/etiología , Hemangiosarcoma/patología , Neoplasias Inducidas por Radiación/patología , Traumatismos por Radiación/patología , Enfermedades Cutáneas Vasculares/etiología , Neoplasias Cutáneas/etiología , Neoplasias Cutáneas/patología , Anciano , Anciano de 80 o más Años , Femenino , HumanosRESUMEN
BACKGROUND: Among heterosexuals, the sexual transmission of human herpesvirus 8 (HHV8) has not been established. OBJECTIVES: To assess HHV8 seroprevalence in spouses of patients with classic and endemic Kaposi sarcoma (KS) and to suggest possible routes of transmission. METHODS: A case-control study was carried out in a teaching hospital among spouses of human immunodeficiency virus-negative patients with KS (cases - exposed subjects) and controls who did not have KS nor were related to patients with KS (nonexposed subjects). HHV8 seroprevalence in spouses of patients with KS was compared with HHV8 seroprevalence in controls matched for age, gender and place of birth. Other serology tests were compared between cases and controls. Among heterosexual couples, HHV8-seropositive and HHV8-seronegative spouses were compared for possible risk factors for virus transmission. RESULTS: HHV8 seroprevalence was significantly higher among spouses of patients with KS (13 of 22; 59%) than among matched controls (19 of 58; 33%; P = 0.043). Among heterosexual couples, five of five (100%) male spouses were HHV8 positive vs. six of 15 (40%) female spouses (P = 0.04). There was no significant difference between HHV8-seropositive and HHV8-seronegative spouses for all other factors screened for among heterosexual couples. CONCLUSIONS: Being a spouse of a patient with KS is a risk factor for HHV8 seropositivity. Our results suggest that female-to-male HHV8 transmission could be more efficient than male-to-female transmission among couples including a patient with KS. Transmission could involve distinctive behaviours, or currently unknown biological properties of HHV8.
Asunto(s)
Herpesvirus Humano 8 , Sarcoma de Kaposi/virología , Enfermedades Virales de Transmisión Sexual/transmisión , Esposos , Adulto , Anciano , Anciano de 80 o más Años , Estudios de Casos y Controles , Femenino , Seronegatividad para VIH , Infecciones por Herpesviridae/transmisión , Infecciones por Herpesviridae/virología , Herpesvirus Humano 8/inmunología , Humanos , Masculino , Persona de Mediana Edad , Reacción en Cadena de la Polimerasa/métodos , Factores de Riesgo , Estudios Seroepidemiológicos , Conducta Sexual/estadística & datos numéricos , Enfermedades Virales de Transmisión Sexual/virologíaRESUMEN
BACKGROUND: Erythema elevatum diutinum is a rare, chronic and recurrent dermatosis affecting adults. The disease is characterized by symmetrical, red, brownish-purple, and yellow papules, plaques, and nodules distributed mainly over the extensor surfaces of the extremities. The aetiology is unknown. The condition can occur in association with haematological malignancies (30%), and most frequently with IgA monoclonal gammapathy. Histological diagnosis is sometimes difficult, especially in the late stages of the disease. We describe an unusual case of erythema elevatum diutinum with clinical and histopathological pseudoneoplastic features. CASE REPORT: A 60-year-old man with no significant medical history consulted for a large nodule of the left knee measuring 2.5cm and red-purple papules symmetrically distributed on the extensor surfaces. Surgical removal of the nodule was performed. The histologic findings were characterized by a predominant concentric fibrosis forming well-circumscribed dermal nodules, composed of small aggregates of spindle cells with palisading and lamellar patterns. Within the nodules, pycnotic polymorphonuclear leucocytes were observed. The nodules were surrounded by a lymphoplasmocytic and histiocytic infiltrate. The diagnosis of erythema elevatum diutinum was thus made and dapsone given, with partial improvement of the lesions. DISCUSSION: This case illustrates the nodular pseudoneoplastic presentation and the difficulty of histological diagnosis, since long-standing lesions can mimic connective tissue tumours. Clues for histopathological diagnosis are neutrophils scattered throughout the lesion, sometimes associated with vasculitis. Extensive investigation should be made for polymorphonuclear leucocytes that are always present, even in late fibrotic lesions.
Asunto(s)
Eritema , Antiinfecciosos/uso terapéutico , Dapsona/administración & dosificación , Dapsona/uso terapéutico , Diagnóstico Diferencial , Eritema/diagnóstico , Eritema/tratamiento farmacológico , Eritema/patología , Eritema/cirugía , Fibrosis/patología , Estudios de Seguimiento , Dermatosis de la Mano/diagnóstico , Dermatosis de la Mano/tratamiento farmacológico , Dermatosis de la Mano/patología , Humanos , Rodilla , Masculino , Persona de Mediana Edad , Neutrófilos , Piel/patología , Neoplasias Cutáneas/diagnóstico , Factores de Tiempo , Resultado del TratamientoRESUMEN
OBJECTIVES: In order to evaluate recurrence rates after a mean follow-up period of five years, the aim of this unicentric prospective study was to collect data of the surgical procedure concerning both skin basal cell carcinomas (BCC) and squamous cell carcinomas (SCC). PATIENTS AND METHOD: Eight hundred and fourty-four patients were included and data were retrospectively analyzed. During the surgical procedure, the peripheral clinical clearance margin was, respectively, 4mm for the skin basal cell carcinomas, 8 mm for the sclerodermiform type and 10mm for the squamous cell carcinomas. RESULTS: Basal cell carcinomas (BCC) were represented in 80% and the most frequent locations were the nasal area (30%). On average, the BCC measured 13.2mm. The peripheral histological clearance margin average was 4.1mm. The rate of recurrence was 3.8% after follow-up at an average of 36 months. Squamous cell carcinomas were represented in 20% cases and their locations were mainly located on the lips, the cheeks, the genital region and the extremities. On average, the SCC measured 22.45 mm. The peripheral histological clearance margin average was 10.26 mm. The rate of recurrence was 5% after follow-up at an average of 33 months. CONCLUSION: In our study, the rate of recurrence was less than 5% after follow-up of five years. To avoid repetitive operations and the risk of recurrence in anatomically sensitive areas, these tumors should be treated with standard wide margins chosen between 4 and 10 mm, function of the histological type.
Asunto(s)
Carcinoma/cirugía , Recurrencia Local de Neoplasia/patología , Neoplasias Cutáneas/cirugía , Adulto , Anciano , Anciano de 80 o más Años , Carcinoma/patología , Femenino , Estudios de Seguimiento , Humanos , Masculino , Persona de Mediana Edad , Estudios Prospectivos , Neoplasias Cutáneas/patología , Adulto JovenAsunto(s)
Inmovilización/efectos adversos , Úlcera de la Pierna/patología , Úlcera por Presión/patología , Anciano , Artroplastia de Reemplazo de Cadera , Biopsia , Cicatriz Hipertrófica/etiología , Cicatriz Hipertrófica/patología , Imagen de Difusión por Resonancia Magnética , Femenino , Fibrosis/etiología , Humanos , Úlcera de la Pierna/etiología , Linfedema/complicaciones , Obesidad/complicaciones , Complicaciones Posoperatorias/diagnóstico , Complicaciones Posoperatorias/patología , MusloRESUMEN
The p16 gene expresses two alternative transcripts (p16alpha and p16beta) involved in tumor suppression via the retinoblastoma (Rb) or p53 pathways. Disruption of these pathways can occur through inactivation of p16 or p53, or activating mutations of cyclin dependant kinase 4 gene (Cdk4). We searched for p16, Cdk4 and p53 gene mutations in 20 squamous cell carcinomas (SSCs), 1 actinic keratosis (AK), and 28 basal cell carcinomas (BCCs), using PCR-SSCP. A deletion and methylation analysis of p16 was also performed. Six different mutations (12%) were detected in exon 2 of p16 (common to p16alpha and p16beta), in five out of 21 squamous lesions (24%) (one AK and four SCCs) and one out of 28 BCCs (3.5%). These included four (66%) ultraviolet (UV)-type mutations (two tandems CC : GG to TT : AA transitions and two C : G to T : A transitions at dipyrimidic site) and two transversions. P53 mutations were present in 18 samples (37%), mostly of UV type. Of these, only two (one BCC and one AK) harboured simultaneously mutations of p16, but with no consequence on p16beta transcript. Our data demonstrate for the first time the presence of p16 UV induced mutations in non melanoma skin cancer, particularly in the most aggressive SCC type, and support that p16 and p53 are involved in two independent pathways in skin carcinogenesis.
Asunto(s)
Inhibidor p16 de la Quinasa Dependiente de Ciclina/genética , Mutación , Neoplasias Glandulares y Epiteliales/genética , Neoplasias Inducidas por Radiación/genética , Proteínas Proto-Oncogénicas , Neoplasias Cutáneas/genética , Rayos Ultravioleta , Empalme Alternativo , Carcinoma Basocelular/genética , Carcinoma de Células Escamosas/genética , Quinasa 4 Dependiente de la Ciclina , Inhibidor p16 de la Quinasa Dependiente de Ciclina/efectos de la radiación , Quinasas Ciclina-Dependientes/genética , Exones , Humanos , Intrones , Mutación/efectos de la radiación , Proteínas/genética , Proteína p14ARF Supresora de Tumor , Proteína p53 Supresora de Tumor/genéticaAsunto(s)
Inestabilidad de Microsatélites , Neoplasias Cutáneas/genética , Neoplasias Cutáneas/inmunología , Carcinoma de Células Escamosas/etiología , Carcinoma de Células Escamosas/genética , Carcinoma de Células Escamosas/inmunología , Humanos , Síndromes de Inmunodeficiencia/complicaciones , Síndromes de Inmunodeficiencia/genética , Sarcoma de Kaposi/genética , Sarcoma de Kaposi/inmunología , Neoplasias Cutáneas/etiología , Trasplantes/efectos adversosRESUMEN
The objectives of this study were to evaluate the outcome after polychemotherapy for patients with primary cutaneous large-cell lymphomas (PCLL) and to validate the recently proposed immunohistologic classification of cutaneous lymphomas. Among 140 patients with positive skin biopsies included in the LNH87 protocol (for treatment of aggressive lymphomas), 49 patients met the criteria of PCLL. Characteristics were: sex ratio M/F, 2.3; age 18 to 83 years (median, 52), peripheral lymph nodes, n=22; diffuse disease, n=12; median tumor size, 4.5 cm; elevated lactate dehydrogenase, n=9; ECOG: 0/1, n=49. Histology was: follicular center B cell, n=23; B-lymphoblastic, n=1; anaplastic large-cell lymphoma, n=14 (T cell phenotype n=8); CD30- T cell lymphoma, n=11. All patients received polychemotherapy: under 70 years, ACVBP (three to four cycles and consolidation for 6 months) n=25; mBACOD (eight cycles) n=16; over 70 years, C(T)VP (six cycles) n=8. Radiation therapy was not included in the protocol. With a median follow-up of 5 years, 24/49 patients had relapsed, with 20 skin relapses. Event-free (EFS) and overall survival (OS) at 5 years were, respectively, 50 and 77%. Significant adverse prognostic factors were: histology (CD30- T cell lymphoma) and diffuse cutaneous disease (>10% of skin). The presence of nodal involvement was only significant for EFS. When compared to 140 non-cutaneous lymphoma patients included in the same trial and fully matched for the main clinical characteristics, OS was similar. In conclusion, PCLL behaves like other localized B or T cell extranodal lymphomas with the same prognostic factors (LDH, ECOG, age) except for CD30+ PCLL which have a very good prognosis.
Asunto(s)
Protocolos de Quimioterapia Combinada Antineoplásica/uso terapéutico , Linfoma de Células B Grandes Difuso/tratamiento farmacológico , Linfoma no Hodgkin/tratamiento farmacológico , Neoplasias Cutáneas/tratamiento farmacológico , Adolescente , Adulto , Anciano , Anciano de 80 o más Años , Bleomicina/administración & dosificación , Estudios de Casos y Controles , Ciclofosfamida/administración & dosificación , Dexametasona/administración & dosificación , Doxorrubicina/administración & dosificación , Femenino , Humanos , L-Lactato Deshidrogenasa/metabolismo , Leucovorina/administración & dosificación , Masculino , Metotrexato/administración & dosificación , Persona de Mediana Edad , Prednisona/administración & dosificación , Pronóstico , Estudios Prospectivos , Resultado del Tratamiento , Vincristina/administración & dosificación , Vindesina/administración & dosificaciónRESUMEN
We report virus-free transfer of a "suicide" gene into tumoral cells. The system can be used in vitro or in vivo to induce tumor cell death. A plasmid carrying the herpes simplex virus thymidine kinase (HSV-TK) gene with its 5'- and 3'-flanking regions was used both alone and in liposomes to transduce B16 cells. In vitro, a 5-day treatment with ganciclovir after transfection with the HSV-TK gene in liposomes induced a significant lysis of B16 melanoma cells as assessed by the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide test. The efficacy of transfection was determined using liposomes harboring the beta-galactosidase reporter gene and was around 10%. Thus, the cytotoxicity observed resulted presumably from a large bystander effect. In vivo, direct transfer of the TK DNA into established B16 melanoma tumors in C57B6 mice followed by i.p. ganciclovir treatment induced a 50% reduction of tumor weight after 8 days and an increased necrosis. Despite the use of the nonspecific strong TK promoter, no necrosis was detected in normal tissues surrounding the tumor or elsewhere. Thus, this system of tumor transfection, which does not involve any viral vector, is safe and straightforward and seems to be suitable for testing in clinical trials.
Asunto(s)
Ganciclovir/uso terapéutico , Terapia Genética , Melanoma Experimental/terapia , Simplexvirus/enzimología , Timidina Quinasa/genética , Animales , Muerte Celular , Técnicas de Transferencia de Gen , Liposomas , Melanoma Experimental/patología , Ratones , Ratones Endogámicos C57BL , Plásmidos , Células Tumorales CultivadasRESUMEN
OBJECTIVE: To evaluate the clinical and biological impact of protease inhibitors on HIV-associated Kaposi's sarcoma. DESIGN AND SETTING: A cohort of 10 patients included prospectively from April 1996 to June 1997 were studied in one institutional centre after initiation of protease inhibitors. PATIENTS AND METHODS: All patients but one (stable disease) had progressive Kaposi's sarcoma. Three out of 10 patients had stopped specific chemotherapy for Kaposi's sarcoma for more than 4 weeks, three were still under chemotherapy, and four had never received specific treatment of Kaposi's sarcoma. Plasma HIV viral load, human herpesvirus (HHV)-8 viraemia in peripheral blood mononuclear cells (PBMC), and CD4 cell count were sequentially assessed from the beginning of therapy. For six patients, a semiquantitative evaluation of HHV-8 viral load in the Kaposi's sarcoma lesions was performed during treatment using polymerase chain reaction. RESULTS: After initiation of HIV triple therapy with protease inhibitors, we observed six complete responses, two partial responses, and two patients with progressive disease. All patients had undetectable plasma HIV viral load within 2 months of treatment. Undetectable HHV-8 viraemia in PBMC occurred in seven out of eight patients with partial or complete response and in none of the progressive patients. A decrease or negation of HHV-8 viral load in Kaposi's sarcoma lesions was observed in two complete responders. CONCLUSION: Our results suggest that antiviral therapy with protease inhibitors are clinically efficient in HIV-associated Kaposi's sarcoma and that there exists a correlation between clinical response and negation of HHV-8 viraemia.
Asunto(s)
Infecciones Oportunistas Relacionadas con el SIDA/tratamiento farmacológico , Fármacos Anti-VIH/uso terapéutico , Didesoxinucleósidos/uso terapéutico , Inhibidores de la Proteasa del VIH/uso terapéutico , Herpesvirus Humano 8 , Indinavir/uso terapéutico , Inhibidores de la Transcriptasa Inversa/uso terapéutico , Ritonavir/uso terapéutico , Saquinavir/uso terapéutico , Sarcoma de Kaposi/tratamiento farmacológico , Infecciones Oportunistas Relacionadas con el SIDA/virología , Adulto , Didanosina/uso terapéutico , Quimioterapia Combinada , Femenino , Humanos , Lamivudine/uso terapéutico , Masculino , Persona de Mediana Edad , Estudios Prospectivos , Sarcoma de Kaposi/virología , Estavudina/uso terapéutico , Resultado del Tratamiento , Carga Viral , Viremia , Zalcitabina/uso terapéutico , Zidovudina/uso terapéuticoRESUMEN
In the treatment of the classical and endemic African forms of Kaposi's sarcoma (KS), radiation therapy and chemotherapy have been widely used with varying degrees of success and morbidity. We here report our preliminary experiences with low doses of recombinant interferon alfa-2b (rIFN alpha-2b) in the treatment of these types of KS, non-linked to the acquired immunodeficiency syndrome (AIDS). Ten consecutive patients (eight patients with classical and two with endemic KS) with a median age of 62 years were treated long-term with 5 X 10(6) units of rIFN alpha-2b (Introna) given subcutaneously three times weekly for at least 6 months. Of the 10 patients, six presented with cutaneous disease only, and four had additional visceral involvement. After 6 months of treatment, seven of the 10 patients had a major response of the cutaneous lesions, and three patients showed stable skin diseases. Of the four patients with additional visceral disease, one patient showed a complete regression of an intramyocardial tumor involving the right atrium and ventricle, whereas in the three other patients stabilization of the visceral lesions with marked symptomatic improvement occurred. On the whole, the long-term results over a median duration of 12 months (range, 7 to 30) are also satisfactory: IFN-alpha continued to control KS in all patients. The treatment was generally well tolerated; no serious side effects were observed. Our preliminary data suggest that low-dose rIFN alpha-2b regimens are effective in classical and endemic African KS. However, further studies are needed to establish the exact role for IFN-alpha as alternative to radiation and chemotherapy.
Asunto(s)
Interferón-alfa/uso terapéutico , Sarcoma de Kaposi/tratamiento farmacológico , Neoplasias Cutáneas/tratamiento farmacológico , Humanos , Interferón alfa-2 , Interferón-alfa/efectos adversos , Proteínas Recombinantes , Sarcoma de Kaposi/patología , Neoplasias Cutáneas/patologíaRESUMEN
We report 3 cases of bullous immunoglobulinic amyloidosis and review 25 published cases. In 2 of our patients, amyloid deposits were not detected with special staining, but by means of ultrastructural methods. Investigations of the skin lesions permitted the diagnosis of associated plasma cell dyscrasia in 2 patients. Unexplained bullous lesions should be investigated for amyloid deposits and the presence of monoclonal gammopathy by methods including electron microscopy and immunochemical analysis of serum and urine.
Asunto(s)
Amiloidosis/diagnóstico , Paraproteinemias/diagnóstico , Enfermedades Cutáneas Vesiculoampollosas/diagnóstico , Anciano , Amiloidosis/complicaciones , Amiloidosis/inmunología , Amiloidosis/metabolismo , Femenino , Humanos , Persona de Mediana Edad , Paraproteinemias/complicaciones , Paraproteinemias/inmunología , Paraproteinemias/metabolismo , Enfermedades Cutáneas Vesiculoampollosas/etiología , Enfermedades Cutáneas Vesiculoampollosas/inmunología , Enfermedades Cutáneas Vesiculoampollosas/metabolismoRESUMEN
The aim of the study was to use a virus-free system to transfer the Herpes Simplex Virus-thymidine kinase (HSV-TK) gene in mice bearing melanoma tumours. B16 F1 murine melanoma cells were injected subcutaneously. On days 11 and 14, an intratumoral injection of either naked plasmid containing the HSV-TK gene (pAG0) or pAG0-lipofectamine complexes was given. Ganciclovir (120 mg/kg/day) was given for 5 days starting on day 14. Tumour weight reduction (40-50%) was observed in treated animals versus different control groups. Moreover, histopathological analysis on tumours showed large areas of cavitary necrosis (85%) in treated groups compared to controls (10%). Using a simple and safe method, the results presented here demonstrated that virus-free mediated delivery of the HSV-TK gene is efficient in vivo in murine malignant melanoma.
Asunto(s)
Técnicas de Transferencia de Gen , Genes Virales/genética , Melanoma Experimental/terapia , Simplexvirus/genética , Timidina Quinasa/genética , Proteínas Estructurales Virales/genética , Animales , Vectores Genéticos , Masculino , Melanoma Experimental/genética , Ratones , Ratones Endogámicos C57BL , Timidina Quinasa/uso terapéuticoRESUMEN
Lymphokine activated killer (LAK) cells were cocultivated from 2 to 6 days with WM266 metastatic melanoma cells maintained as nodules in organotypic culture. The LAK cells in suspension were allowed to deposit freely on the nodule surface from where they could infiltrate spontaneously into the nodules. Immunohistochemical studies were done to localize the LAK cells as well as electron microscopical observations for effector/target membrane contacts. Proliferation of the nodules was tested and also that of the LAK cells after coculturing using tritiated thymidine incorporation into DNA. Cell death was determined by arrest of thymidine incorporation and total nodule disintegration. Infiltration rate of LAK cells into the nodules was low: after coculturing 5% of the nodule cells were LAK cells. Although close membrane contacts and cytoplasmic fusions between effector and target cells leading to tumor cell apoptosis were observed, this direct cytolytic process seemed to be too infrequent for the induction of total nodule disintegration at day 6. Therefore, the indirect pathway to cytolysis might be predominant implying, among other cytokines, soluble TNF. On the other hand, LAK cell proliferation diminished strongly after coculturing (down to 11%) but the cytotoxicity was significantly enhanced (18% higher) suggesting an enhancement of differentiation. This might account for the peculiar efficacy of LAK cells on melanomas in vivo and it would be of interest to study this phenomenon further.
RESUMEN
Treatment of cutaneous T-cell and B-cell lymphomas is difficult and relapses are frequent. To evaluate the efficiency of high-dose therapy (HDT) and autologous stem cell transplantation (ASCT) on relapsing cutaneous lymphomas, we conducted a retrospective study of 14 patients. We investigated the clinical and histological parameters of the lymphoma, previous treatments to ASCT, short-term complications of ASCT, and occurrence of a relapse. There were 11 males and three females, with a median age of 42 years. Most often, the skin disease was disseminated without extracutaneous involvement. Four patients had a B-cell lymphoma and 10 a T-cell lymphoma. CD30 was negative in 8/10 T-cell lymphomas. Before ASCT, 13 patients had chemosensitive disease; one had refractory disease. The conditioning regimen included TBI in nine cases. No toxic death occurred. Relapse of the lymphoma occurred in eight cases (T-cell lymphoma in seven cases), within 4 months after ASCT in six cases. Relapses were treated with local treatment, interferon or classical chemotherapy. At the end of the study, 11 patients were alive and three patients had died. HDT and ASCT do not benefit patients with T-cell lymphomas. For patients with disseminated relapsing cutaneous B-cell lymphomas, this procedure should be considered.
Asunto(s)
Linfoma de Células B/terapia , Linfoma de Células T/terapia , Neoplasias Cutáneas/terapia , Trasplante de Células Madre/métodos , Adulto , Niño , Femenino , Humanos , Linfoma de Células B/patología , Linfoma de Células T/patología , Masculino , Persona de Mediana Edad , Recurrencia , Estudios Retrospectivos , Neoplasias Cutáneas/patología , Acondicionamiento Pretrasplante/métodos , Trasplante AutólogoRESUMEN
BACKGROUND: Kaposi's sarcoma is considered to be an angioproliferative disease associated with a novel herpesvirus (KSHV/HHV8), but the precise pathophysiology of the lesion remains unclear. The study of clonality in Kaposi's sarcoma using X linked DNA polymorphism has been difficult so far, because of a very strong prevalence of the disease in males. AIMS: To study the clonality of Kaposi's sarcoma lesions. METHODS: An assay based on a methyl sensitive restriction digest followed by polymerase chain reaction (PCR) amplification of the highly polymorphic human androgen receptor (HUMARA) gene was used. Tissues from Kaposi's sarcoma lesions and control tissues from the same patients were obtained from seven females, four with classic Kaposi's sarcoma and three with AIDS associated Kaposi's sarcoma. A cutaneous angiosarcoma was also analysed, for comparative purposes, and showed evidence of clonality after HpaII digestion. RESULTS: All patients were heterozygous for the HUMARA polymorphism and informative for analysis. In all patients, including four with a nodular form of Kaposi's sarcoma and more than 70% spindle cells in the lesion, a polyclonal pattern of inactivation could be demonstrated. CONCLUSIONS: The Kaposi's sarcoma lesion is first of all a polyclonal cell proliferation.
Asunto(s)
Células Madre Neoplásicas/patología , Sarcoma de Kaposi/genética , Neoplasias Cutáneas/genética , Síndrome de Inmunodeficiencia Adquirida/complicaciones , Femenino , Ligamiento Genético , Humanos , Reacción en Cadena de la Polimerasa , Polimorfismo Genético , Receptores Androgénicos/genética , Sarcoma de Kaposi/patología , Sarcoma de Kaposi/virología , Neoplasias Cutáneas/patología , Neoplasias Cutáneas/virología , Cromosoma X/genéticaRESUMEN
AIMS: To investigate the effects of slide storage on immunohistochemical staining, since recent reports have indicated that storage of unstained paraffin slides for up to 12 weeks may lead to false negative immunostaining of tumour markers. METHODS: 11 antibodies (anti-cytokeratin, epithelial membrane antigen (EMA), vimentin, smooth muscle actin, PS100, chromogranin, CD45, CD20, CD3, CD30, and oestrogen receptor (OR) were tested on unstained paraffin slides of breast carcinomas, lymphomas, and neuroendocrine tumours that had been stored for three to 10 years. All the paraffin blocks were recut less than one week before immunostaining. Immunostainings of years old slides were compared with those of recent slides in at least five cases for each antibody. For three antibodies (antichromogranin, anti-CD3, and anti-OR) we also tested one year old and three months old slides. RESULTS: Intensity of staining on years old slides was strikingly reduced for chromogranin and CD3 in several cases and was slightly stronger for vimentin. In some cases a significant decrease of OR positivity was observed after three months storage, and a complete loss of OR immunostaining after 12 months. No significant difference was noted with the other antibodies. CONCLUSIONS: Immunohistochemical detection of some antigens located either in the nucleus, in the cytoplasm, or on the cytoplasmic membrane could be impaired by storage of paraffin slides as short a time as three months. One should be cautious of doing retrospective immunohistochemical studies on stored unstained slides.
Asunto(s)
Antígenos de Neoplasias/análisis , Biomarcadores de Tumor/análisis , Adhesión en Parafina , Conservación de Tejido , Neoplasias de la Mama/química , Complejo CD3/análisis , Cromograninas/análisis , Femenino , Humanos , Técnicas para Inmunoenzimas , Linfoma/química , Tumores Neuroendocrinos/química , Receptores de Estrógenos/análisis , Coloración y Etiquetado , Factores de TiempoRESUMEN
We evaluated a patient in whom pachydermoperiostosis occurred in conjunction with anemia and gastric hypertrophy. The mechanism of the anemia appears multifactorial because, besides a myelofibrosis, a serum inhibitor of the late stage of erythropoiesis was detected. The elevated serum bone Gla-protein (osteocalcin) favors the hypothesis that primary hypertrophic osteoarthropathy represents an imbalance between increased osteoblastic bone formation and normal bone resorption.
Asunto(s)
Anemia/complicaciones , Proteínas de Unión al Calcio/sangre , Mucosa Gástrica/patología , Osteoartropatía Hipertrófica Primaria/complicaciones , Adulto , Biopsia , Humanos , Hipertrofia , Masculino , Osteoartropatía Hipertrófica Primaria/sangre , Osteoartropatía Hipertrófica Primaria/genética , Osteoartropatía Hipertrófica Primaria/patología , Osteocalcina , Mielofibrosis Primaria/complicacionesRESUMEN
BACKGROUND: Epstein-Barr virus (EBV) has been demonstrated in angiocentric immunoproliferative lesions, suggesting that it could be a causative factor. We investigated for the presence of EBV in 12 primary and 2 secondary cutaneous angiocentric lymphomas (CALs). OBSERVATIONS: In the 2 secondary CALs, strong reactivity for EBV RNAs and latent membrane protein 1 were detected on paraffin-embedded sections. In contrast, 10 of 12 primary CALs were completely negative for EBV RNAs and latent membrane protein 1. In 2 primary CALs, EBV RNAs and latent membrane protein 1 were detected in few tumor cells. In the group of primary CALs, 8 of 12 were still alive at last follow-up, 3 died of systemic lymphoma, and 1 died of another cause, whereas both patients with secondary CALs died of disease within 1 year. CONCLUSION: Differences in the presence of EBV and clinical behavior between primary and secondary CALs suggest that different mechanisms are operative in the pathogenesis of these conditions, and indicate that the 2 groups should be considered separately.